<DOC>
	<DOCNO>NCT00035113</DOCNO>
	<brief_summary>This study examine whether new investigational drug EPO906 , give intravenous infusion ( IV directly vein ) , effective shrinking tumor prevent growth cell cause prostate cancer .</brief_summary>
	<brief_title>EPO906 Therapy Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>The following patient may eligible study : Patients histologically proven prostate cancer measurable metastatic disease PSA progression &gt; 20ng/ml initial hormonal therapy eligible Patients must maintain androgen ablation therapy LHRH agonist undergone orchiectomy Patients bicalutamide flutamide recently withdraw must demonstrate progression disease least 6 week 4 week respectively , beyond discontinuation agent Patients take PCSPES must discontinue therapy minimum 4 week For patient disease progression define solely PSA increase : two consecutive rise PSA measurement , 4week period ( separate previous 2 week ) last measurement must least 50 % great nadir PSA achieve last therapeutic maneuver For patient discontinue bicalutamide therapy prior study entry , third rise PSA measurement require 2 week second PSA measurement ( i.e . 6 week period ) Must life expectancy great three ( 3 ) month Bilirubin must within normal limit . Transaminases ( SGOT and/or SGPT ) may 2.5 X institutional upper limit normal alkaline phosphatase less upper limit normal , alkaline phosphatase may 4 X upper limit normal transaminase less equal upper limit normal For patient disease progression define measurable disease : change measurable size lymph node parenchymal mass physical radiologic examination ( bone scan finding adequate ass measurable disease ) . The following patient eligible study : Patients symptomatic CNS metastasis leptomeningeal involvement Patients peripheral neuropathy unresolved diarrhea great Grade 1 Patients severe cardiac insufficiency Patients take Coumadin warfarincontaining agent exception low dose Coumadin ( 1 mg less ) maintenance indwell line port Patients receive palliative radiotherapy tumor locate centrally less 4 week ( 28 day ) prior plan enrollment date ( palliative radiotherapy isolate peripheral bone metastasis allow ) Patients experience hormone withdrawal syndrome , 28 day postwithdrawal antiandrogen therapy ( 42 day bicalutamide ) Patients one prior chemotherapy regimen hormoneresistant metastatic disease Patients disease measurable bone scan Patients receive corticosteroid within past 28 day ( may waive approval Novartis ) History another malignancy within 5 year prior study entry except curatively treat nonmelanoma skin cancer Patients undergone major surgery cause le 4 week prior study entry Patients radiation therapy chemotherapy within last four week Patients active suspect acute chronic uncontrolled infection include abcesses fistulae HIV+ patient</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>androgen independent</keyword>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>tumour</keyword>
	<keyword>neoplasm</keyword>
	<keyword>carcinoma</keyword>
	<keyword>intravenous</keyword>
	<keyword>epothilone</keyword>
</DOC>